Springer Protocols: Abstract: 15. Regulated Expression of Adenoviral Vectors-Based Gene Therapies: Therapeutic Expression of Toxins and Immune-Modulators

15. Regulated Expression of Adenoviral Vectors-Based Gene Therapies: Therapeutic Expression of Toxins and Immune-Modulators

By: James F. Curtin³, Marianela Candolfi³, Mariana Puntel³, Weidong Xiong³, A.K.M. Muhammad³, Kurt Kroeger³, Sonali Mondkar³, Chunyan Liu³, Niyati Bondale³, Pedro R. Lowenstein³, Maria G. Castro³

Abstract

Full Text

Download PDF (917K)

Regulatable promoter systems allow gene expression to be tightly controlled in vivo. This is highly desirable for the development of safe, efficacious adenoviral vectors that can be used to treat human diseases in the clinic. Ideally, regulatable cassettes should have minimal gene expression in the “OFF” state, and expression should quickly reach therapeutic levels in the “ON” state. In addition, the components of regulatable cassettes should be non-toxic at physiological concentrations and should not be immunogenic, especially when treating chronic illness that requires long-lasting gene expression. In this chapter, we will describe in detail protocols to develop and validate first generation (Ad) and high-capacity adenoviral (HC-Ad) vectors that express therapeutic genes under the control of the TetON regulatable system. Our laboratory has successfully used these protocols to regulate the expression of marker genes, immune stimulatory genes, and toxins for cancer gene therapeutics, i.e., glioma that is a deadly form of brain cancer. We have shown that this third generation TetON regulatable system, incorporating a doxycycline (DOX)-sensitive ${\rm rtTA}_{2}^{\rm S}-M2$ inducer and ${\rm tTS}^{\rm Kid}$ silencer, is non-toxic, relatively non-immunogenic, and can tightly regulate reporter transgene expression downstream of a TRE promoter from adenoviral vectors in vitro and also in vivo.

Affiliation(s): (3) The Board of Governors’ Gene Therapeutics Research Institute, Cedars-Sinai Medical Center and Department of Molecular, Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA

Book Title: Gene Therapy Protocols: Design and Characterization of Gene Transfer Vectors

Series: Methods in Molecular Biology | Volume: 434 | Pub. Date: Mar-07-2008 | Page Range: 239-266 | DOI: 10.1007/978-1-60327-248-3_15

Subject: Genetics/Genomics

Key Words: Adenoviral vectors - tetracycline - TetON - inducible - regulatable - gene therapy - doxycycline - glioma - Pseudomonas exotoxin A (PE)

References

Download References

1.	Wurm, F. M., Gwinn, K. A., and Kingston, R. E. (1986) Inducible overproduction of the mouse c-myc protein in mammalian cells, Proc Natl Acad Sci USA 83, 5414–8.

2.	Rivera, V. M., Clackson, T., Natesan, S., Pollock, R., Amara, J. F., Keenan, T., Magari, S. R., Phillips, T., Courage, N. L., Cerasoli, F., Jr., Holt, D. A., and Gilman, M. (1996) A humanized system for pharmacologic control of gene expression, Nat Med 2, 1028–32.

3.	Molin, M., Shoshan, M. C., Ohman-Forslund, K., Linder, S., and Akusjarvi, g. (1998) Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments, J Virol 72, 8358–61.

4.	Goverdhana, S., Puntel, M., Xiong, W., Zirger, J. M., Barcia, C., Curtin, J. F., Soffer, E. B., Mondkar, S., King, g. D., Hu, J., Sciascia, S. A., Candolfi, M., Greengold, D. S., Lowenstein, P. R., and Castro, M. g. (2005) Regulatable gene expression systems for gene therapy applications: progress and future challenges, Mol Ther 12, 189–211.

5.	Xiong, W., Goverdhana, S., Sciascia, S. A., Candolfi, M., Zirger, J. M., Barcia, C., Curtin, J. F., King, g. D., Jaita, g., Liu, C., Kroeger, K., Agadjanian, h., Medina-Kauwe, L., Palmer, D., ng, P., Lowenstein, P. R., and Castro, M. g. (2006) Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses, J Virol 80, 27–37.

6.	Knott, A., Garke, K., Urlinger, S., Guthmann, J., Muller, Y., Thellmann, M., and Hillen, W. (2002) Tetracycline-dependent gene regulation: combinations of transregulators yield a variety of expression windows, Biotechniques 32, 796, 98, 800 passim.

7.	Urlinger, S., Baron, U., Thellmann, M., Hasan, M. T., Bujard, h. and Hillen, W. (2000) Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity, Proc Natl Acad Sci U S A 97, 7963–8.

8.	Freundlieb, S., Schirra-Muller, C., and Bujard, h. (1999) A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells, J Gene Med 1, 4–12.

9.	Lamartina, S., Silvi, L., Roscilli, g., Casimiro, D., Simon, A. J., Davies, M. E., Shiver, J. W., Rinaudo, C. D., Zampaglione, I., Fattori, E., Colloca, S., Gonzalez Paz, O., Laufer, R., Bujard, h., Cortese, R., Ciliberto, g., and Toniatti, C. (2003) Construction of an rtTA2(s)-m2/tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates, Mol Ther 7, 271–80.

10.	Candolfi, M., Curtin, J. F., Xiong, W. D., Kroeger, K. M., Liu, C., Rentsendorj, A., Agadjanian, h., Medina-Kauwe, L., Palmer, D., ng, P., Lowenstein, P. R., and Castro, M. g. (2006) Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells, Mol Ther 14, 371–81.

11.	Candolfi, M., Pluhar, g. E., Kroeger, K., and Puntel, M. C. J., Barcia, C., Muhammad, A.G., Xiong, W., Liu, C., Mondkar, S., Kuoy, W., Kang, T., McNeil, EA., Freese, A. B., Ohlfest J. R., Moore, P., Palmer, D. ng. P., Young, J.D., Lowenstein, P.R., Castro, M.G. (2006) Optimization of adenoviral vector mediated expression in the canine brain in vivo, and in canine glioma cells in vitro., Neuro-oncology Under Review.

12.	Joseph Sambrook, and Russell, D. W. (2001) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Woodbury, NY, USA.

13.	Umana, P., Gerdes, C. A., Stone, D., Davis, J. R., Ward, D., Castro, M. g., and Lowenstein, P. R. (2001) Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination, Nat Biotechnol 19, 582–5.

14.	Maleniak, T. C., Darling, J. L., Lowenstein, P. R., and Castro, M. g. (2001) Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU, Cancer Gene Ther 8, 589–98.

15.	Ali, S., Curtin, J. F., Zirger, J. M., Xiong, W., King, g. D., Barcia, C., Liu, C., Puntel, M., Goverdhana, S., Lowenstein, P. R., and Castro, M. g. (2004) Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression, Mol Ther 10, 1071–84.

16.	Williams, J. C., Stone, D., Smith-Arica, J. R., Morris, I. D., Lowenstein, P. R., and Castro, M. g. (2001) Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas, Mol Ther 4, 593–602.

17.	Smith-Arica, J. R., Morelli, A. E., Larregina, A. T., Smith, J., Lowenstein, P. R., and Castro, M. g. (2000) Cell-type-specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression, Mol Ther 2, 579–87.

18.	Southgate, T. D., Kingston, P. A., and Castro, M. g. (2000) Gene Transfer into Neural Cells In Vitro using Adenoviral Vectors, John Wiley Sons, Inc., New York.

19.	Palmer, D., and ng, P. (2003) Improved system for helper-dependent adenoviral vector production, Mol Ther 8, 846–52.

20.	Ng, P., Parks, R. J., Cummings, D. T., Evelegh, C. M., and Graham, F. L. (2000) An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method, Hum Gene Ther 11, 693–9.

21.	Li, Y., McCadden, J., Ferrer, F., Kruszewski, M., Carducci, M., Simons, J., and Rodvriguez, R. (2002) Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer, Cancer Res 62, 2576–82.

22.	Kohno, K., and Uchida, T. (1987) Highly frequent single amino acid substitution in mammalian elongation factor 2 (EF-2) results in expression of resistance to EF-2-ADP-ribosylating toxins, J Biol Chem 262, 12298–305.

23.	Puntel, M., Curtin, J. F., Zirger, J. M., Muhammad, A. K., Xiong, W., Liu, C., Hu, J., Kroeger, K. M., Czer, P., Sciascia, S., Mondkar, S., Lowenstein, P. R., and Castro, M. g. (2006) Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction, Hum Gene Ther 17, 531–44.

24.	Gerdes, C. A., Castro, M. g., and Lowenstein, P. R. (2000) Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo, Mol Ther 2, 330–8.

25.	Schiedner, g., Morral, N., Parks, R. J., Wu, Y., Koopmans, S. C., Langston, C., Graham, F. L., Beaudet, A. L., and Kochanek, S. (1998) Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity, Nat Genet 18, 180–3.

Comments (Loading...)

Post comment/View all comments